Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect

Diabetic Medicine

Volumn 15, Issue 2, 1998, Pages 120-124

  Ranganath, L ^a   Morris, F ^b   Morgan, L ^b   Wright, J ^b   Marks, V ^b  

^a EPSOM GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Acarbose; Gastric emptying; GLP 1; Paracetamol; Sucrose

Indexed keywords

ACARBOSE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METHIONINE; PAMETON; PARACETAMOL; SUCROSE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; STOMACH EMPTYING;

ACARBOSE; ACETAMINOPHEN; BLOOD GLUCOSE; DIETARY SUCROSE; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; REFERENCE VALUES; TRISACCHARIDES;

EID: 0031883091     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199802)15:2<120::AID-DIA529>3.0.CO;2-I     Document Type: Article

References (26)

1. Leonhardt W, Hanefeld M, Fischer S, Schulze J. Efficacy of α-glucosidase inhibitors on serum lipids in NIDDM subjects with moderate hyperlipidaemia. Eur J Clin Invest 1994; 24: 45-49.
2. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidaemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinaemic subjects. Metabolism 1996; 45: 731-737.
3. Bischoff H. Pharmacology of α-glucosidase inhibition. Eur J Clin Invest 1994; 24: 3-10.
4. Santeusanio F, Compagnucci P. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus. Drug Safety 1994; 11: 432-444.
5. Puls W, Keup V, Krause HP, Thoms G, Hoffmeister F. Glucosidase inhibition: a new approach to the treatment of diabetes, obesity and hyperlipoproteinaemia. Naturwissenschafter 1977; 64: 536-537.
6. Ruppin H, Hagel J, Feuerbach W, et al. Fate and effects of the α-glucosidase inhibitor acarbose in humans. Gastroenterology 1988; 95: 93-99.
7. Hiele M, Ghoos Y, Rutgeerts P, Vantrappen G. Effects of acarbose on starch hydrolysis: study in healthy subjects, ileostomy patients, and in vitro. Digestive Diseases Sciences 1992; 37: 1057-1064.
8. Ladas SD, Frydas A, Papadopoulos A, Raptis SA. Effects of α-glucosidase inhibitors on mouth to caecum transit time in humans. GUT 1992; 33: 1246-1248.
9. Heading RC, Nimmo J, Prescott LF, Tothill P. The dependence of paracetamol absorption on the rate of gastric emptying. Br I Pharmac 1973; 47: 415-421.
10. Gainsborough N, Maskrey VL, Nelson ML, Keating J, Sherwood RA, Jackson SHD, Swift CG. The association of age with gastric emptying. Age and Ageing 1993; 22: 37-40.
11. Macfie AG, Magides AD, Richmond MN, Reilly CS. Gastric emptying in pregnancy. Br J Anaesthesia 1991; 67: 54-57.
12. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-166.
13. Morgan LM, Morris BA, Marks V. Radioimmunoassay of gastric inhibitory polypeptide. Ann Clin Biochem 1978; 15: 172-177.
14. Hampton SM, Withey L. Monitoring B-cell responses in obese and normal weight subjects: a pilot study. Diabete et Metabolisme 1993; 19: 582-585.
15. Turnberg LA. The pathophysiology of diarrhoea. North Am Clin Gastroenterol 1979; 8: 551-568.
16. Scheen AJ, de Magalhaes ACFA, Salvatore T, Lefebvre PJ. Reduction of the acute bioavailability of metformin by the α-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994; 24: 50-54.
17. Jenkins DJA, Taylor RH, Goff DV, Fielden H, Misiewicz JJ, Sarson DL, et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 1981; 30: 951-954.
18. Gerard J, Lefebvre PJ, Luyckx AS. Glibenclamide pharmacology in acarbose-treated type 2 diabetics. Eur J Clin Pharmacol 1984; 27: 233-236.
19. Hillebrand I, Graefe KH, Bischoff H, Frank G, Raemsche KD, Berchtold P. Serum digoxin and propranolol levels during acarbose treatment. Diabetologia 1981; 21: 282.
20. Morgan LM, Tredger JAT, Hampton SM, French AP, Peake JCF, Marks V. The effect of dietary modification and hyperglycaemia on gastric emptying and gastric inhibitory polypeptide (GIP) secretion. Br J Nutrition 1988; 60: 29-37.
21. MaGregor IL, Gueller R, Watts HD, Meyer JM. The effect of acute hyperglycaemia on gastric emptying in man. Gastroenterology 1976; 70: 190-196.
22. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide-1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. Scand J Gastroenterol 1995; 30: 892-896.
23. Layer P, Holst JJ. GLP-1: a humoral mediator of the ileal brake in humans. Digestion 1993; 54: 385-386.
24. Schira J, Wank U, Houck P, Arnold R, Goke B, Katschinski M. Effects of GLP-1 on human antro-pyloroduodenal motility (Abstract). Regulatory Peptides 1996; 64: 170.
25. Brown JC, Munt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiology 1970; 209: 57-64.
26. Wolfe MM, Hocking MP, Maico DG, McGuigan JE. Effects of antibodies to gastric inhibitory peptide on gastric acid secretion and gastrin release in the dog. Gastroenterology 1983; 84: 941-948.